Background And Objectives: Estimating equations for calculating glomerular filtration rate (eGFR) occasionally identify patients with elevated eGFR, yet the prognostic significance remains to be determined. This study sought to define the association of an elevated eGFR on the risk for death and cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease.

Design, Setting, Participants, & Measurements: Data from 8941 subjects who had a history of atherosclerotic vascular disease and were enrolled in the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion trial were analyzed. Time to the composite end point of death, congestive heart failure, myocardial infarction, or stroke was modeled using Cox proportion hazards regression. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease and Cockcroft-Gault formulas.

Results: Compared with subjects with eGFR of 100 to 125 ml/min per 1.73 m2, subjects with eGFR > or = 125 (n = 462) were younger, female, and nonwhite. In addition, subjects with an elevated eGFR were more likely to have diabetes and congestive heart failure. In adjusted analyses, every 10-ml/min per 1.73 m2 decrease in eGFR < 100 was associated with a 13% increased hazard for the composite end point. In addition, every 10-ml/min per 1.73 m2 increase in eGFR > or = 100 was associated with a 9% increased hazard for the composite end point.

Conclusions: In individuals with a history of vascular disease, the relationship between eGFR and cardiovascular outcomes may be parabolic, with increased risk among patients with both reduced and elevated eGFR.

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.00930207DOI Listing

Publication Analysis

Top Keywords

elevated egfr
16
cardiovascular outcomes
12
glomerular filtration
12
filtration rate
12
egfr 100
12
egfr
10
outcomes subjects
8
subjects atherosclerotic
8
atherosclerotic cardiovascular
8
vascular disease
8

Similar Publications

CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD/NADH ratio.

J Exp Clin Cancer Res

January 2025

School of Medicine, Chinese PLA General Hospital, Nankai University, Beijing, China.

Background: Glioblastoma multiforme (GBM) exhibits a cellular hierarchy with a subpopulation of stem-like cells known as glioblastoma stem cells (GSCs) that drive tumor growth and contribute to treatment resistance. NAD(H) emerges as a crucial factor influencing GSC maintenance through its involvement in diverse biological processes, including mitochondrial fitness and DNA damage repair. However, how GSCs leverage metabolic adaptation to obtain survival advantage remains elusive.

View Article and Find Full Text PDF

Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness.

Int J Biol Sci

January 2025

Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 610041.

Article Synopsis
  • The study addresses a common issue in lung cancer treatment, where patients develop resistance to EGFR-TKIs like gefitinib, leading to worse outcomes.
  • The researchers developed a novel therapy using folic acid-modified milk exosomes loaded with c-kit siRNA (FA-mExo-siRNA-c-kit) to counteract this resistance by targeting the c-kit gene, which is linked to stemness traits in cancer cells.
  • Results showed that this approach not only reduced c-kit expression and stemness characteristics but also slowed tumor growth and improved survival in experimental models, highlighting its potential as a new treatment strategy for resistant lung cancer.
View Article and Find Full Text PDF
Article Synopsis
  • Sinonasal inverted papilloma (SNIP) has a high recurrence rate and the potential to become malignant, but its specific metabolic pathways and biomarkers are not fully understood.
  • RNA sequencing identified significant gene alterations related to the estrogen biosynthesis pathway and highlighted five key biomarkers (AKR1B10, CYP1B1, CYP2C19, CYP3A5, and HSD17B13) that were correlated with SNIP pathogenesis.
  • Functional analysis indicated that these biomarkers are involved in epithelial cell proliferation and EGFR signaling regulation, suggesting their potential as diagnostic and therapeutic targets for managing SNIP.
View Article and Find Full Text PDF

Use of Statins for Primary Prevention Among Individuals with CKD in the United States: A Cross-Sectional, Time-Trend Analysis.

Am J Kidney Dis

December 2024

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland. Electronic address:

Rationale & Objective: Chronic kidney disease (CKD) populations face an elevated risk of cardiovascular disease (CVD), yet many remain undertreated with statins for primary prevention of CVD despite meeting eligibility criteria. We examined trends in statin use for primary prevention among individuals with CKD before and after the release of the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommending statin use for lipid management in selected adults with CKD.

Study Design: Cross-sectional time-trend analysis.

View Article and Find Full Text PDF

Background/aim: Soft tissue sarcoma (STS) is a mesenchymal tumor affecting multiple organs in dogs. Previous studies identified activation of the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (PKB, AKT) pathway in canine STS cell lines and clinical samples, but the underlying mechanism remains unclear. This study investigated PTEN loss, PIK3CA mutation, and EGFR over-expression as potential drivers of PI3K/AKT pathway activation in STS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!